Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Latest Information Update: 13 Jul 2023
At a glance
- Drugs Nivolumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel; Pertuzumab; Trastuzumab
- Indications HER2 negative breast cancer; HER2 positive breast cancer; Inflammatory breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 30 Jun 2023 Status changed from active, no longer recruiting to completed.
- 21 Oct 2022 Planned End Date changed from 1 Jun 2025 to 1 May 2023.
- 21 Oct 2022 Planned primary completion date changed from 1 Jun 2025 to 1 May 2023.